Vir Biotechnology Reports Q4 2025 Results, Announces Astellas Collaboration on VIR-5500
Vir Biotechnology reported Q4 EPS of ($0.31), beating estimates by $0.23, with revenue of $64.07 million. The company announced a global strategic collaboration with Astellas for VIR-5500 and reported $781.6 million in cash and investments.